Maiden Therapeutics
AI-driven discovery of small molecule therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Seed | ||
| Total Funding | 000k | ||
Maiden Therapeutics, now operating as BluMaiden Biosciences, is a biotechnology company headquartered in Singapore that focuses on small molecule drug discovery. The company, founded in 2019 by Damien Keogh, Rohan Williams, and Robert Meyer, utilizes its proprietary platform, MAIDENTM, which integrates computational biology and chemistry to analyze the human microbiome for therapeutic candidates. Initially, the company used human milk from Asian mothers as a primary source for discovery, aiming to address the underrepresentation of Asian microbiomes in research.
The company's business model involves providing pharma services that generate clinical insights for trial decision-making, which in turn feeds its drug discovery division with human-first evidence. This strategy aims to create early revenue while pursuing biotech opportunities. BluMaiden's technology includes an AI model named QuantumBridgeAI™, which translates genomic data into small molecules to identify new bioactive natural products. The platform is designed to probe traditionally "undruggable" targets. Their clients are pharmaceutical and life science companies.
Dr. Damien Keogh, a founder, previously served as CEO and is now the Chief Operations Officer, following the appointment of a US-based leadership team to drive global expansion. The leadership team includes Chairman Michael Tilman, a former Roche Diagnostics CEO, and interim CEO Dr. Terence Kelly. In July 2024, BluMaiden secured a significant investment led by deep-tech VC firm Elev8.vc and SEEDS Capital to accelerate commercialization in Singapore and the US. The company also has a partnership with Zymo Research to offer end-to-end clinical trial analytics and reporting services based on the human microbiome.
Keywords: small molecule drug discovery, AI drug discovery, human microbiome, computational biology, computational chemistry, bioinformatics, therapeutics, clinical trial analytics, pharma services, undruggable targets, natural products, genomics, reverse translation, drug development, oncology, inflammatory disease, metabolic biology, microbiome analysis, precision medicine, life sciences